2021 ARIA-ITALY Multidisciplinary Consensus: Nasal Polyposis & Biological Treatments (Structured Summary)
This consensus (published in World Allergy Organ J, 2021) focuses on type 2 inflammation-driven chronic rhinosinusitis with nasal polyps (CRSwNP), standardizing the selection, initiation, monitoring, and multidisciplinary management of biologic therapies (monoclonal antibodies, mAbs) for refractory cases, with a core principle of reserving biologics for patients failing conventional treatments. Below is a structured, evidence-based synopsis.
1. Core Background & Endotype Definition
-
Pathogenesis: CRSwNP is strongly linked to type 2 inflammation, characterized by elevated eosinophils, IgE, IL-4, IL-5, IL-13, and comorbidities (severe asthma, aspirin-exacerbated respiratory disease [AERD], atopy).
-
Consensus Scope: Addresses mAbs targeting key type 2 inflammatory pathways (IgE, IL-5, IL-5Rα, IL-4Rα) for adult CRSwNP; excludes non-type 2/non-eosinophilic CRSwNP, pediatric patients, and cystic fibrosis-related polyposis.
-
Multidisciplinary Approach: Mandates collaboration between otolaryngologists, allergists, pulmonologists, and immunologists for patient selection, biomarker testing, and long-term monitoring.
2. Biologic Therapy Indications & Contraindications
2.1 Definitive Indications (All Criteria Must Be Met)
-
Confirmed CRSwNP with type 2 inflammation (peripheral eosinophilia ≥300 cells/μL, tissue eosinophilia ≥10%, elevated total IgE, or high FeNO in asthmatics).
-
Refractory to maximal conventional therapy:
-
≥3 months of high-dose intranasal corticosteroids (INCS).
-
Short-course oral corticosteroids (≤2 weeks) with inadequate response.
-
Endoscopic sinus surgery (ESS) for ostial patency restoration, with recurrence within 12 months despite postoperative care (saline irrigation + INCS).
-
Persistent severe symptoms: SNOT-22 score ≥30, nasal obstruction VAS ≥7/10, or anosmia/hypoosmia affecting quality of life.
-
Comorbid severe asthma/AERD with uncontrolled respiratory symptoms despite optimal asthma therapy.
2.2 Contraindications
-
Severe hypersensitivity to mAbs or excipients.
-
Active systemic infections (e.g., tuberculosis, invasive fungal disease, HIV).
-
Malignancies (past 5 years, except basal cell carcinoma).
-
Pregnancy/lactation (insufficient safety data).
-
Non-type 2 CRSwNP (no eosinophilic/IgE-driven inflammation).
3. Biologic Agents: Selection & Dosing (Italy-approved 2021)
|
Biologic |
Target |
Dose & Administration |
Key Efficacy Outcomes |
Biomarker Correlation |
|
Omalizumab |
IgE |
150–375 mg SC q2–4w (based on IgE/weight) |
Reduces polyp size, improves SNOT-22; effective in atopic CRSwNP |
High total IgE (≥100 IU/mL); allergic sensitization |
|
Mepolizumab |
IL-5 |
100 mg SC q4w |
Sustained eosinophil reduction; improves nasal obstruction/olfaction |
Peripheral eosinophilia ≥300 cells/μL; tissue eosinophilia |
|
Benralizumab |
IL-5Rα |
30 mg SC q4w (loading: 3 doses q4w; maintenance: q8w) |
Rapid eosinophil depletion; reduces exacerbations in CRSwNP + asthma |
Peripheral/tissue eosinophilia; severe asthma overlap |
|
Dupilumab |
IL-4Rα |
300 mg SC q2w (loading: 600 mg SC) |
Largest evidence base for CRSwNP; improves all symptoms (obstruction, rhinorrhea, olfaction) |
Type 2 inflammation (any biomarker); first-line for AERD |
3.1 Selection Algorithm
-
First-line: Dupilumab (highest efficacy across CRSwNP phenotypes; preferred for AERD).
-
Second-line: Mepolizumab/benralizumab (eosinophil-predominant CRSwNP without AERD).
-
Third-line: Omalizumab (atopic CRSwNP with high IgE and comorbid allergic asthma).
4. Pre-Treatment Workup & Monitoring
4.1 Pre-Treatment Assessment (Within 4 Weeks)
|
Test Category |
Mandatory Tests |
Rationale |
|
Biomarkers |
Peripheral eosinophils, total IgE, FeNO (asthmatics) |
Confirm type 2 inflammation; guide agent selection |
|
Imaging |
Sinus CT (Lund-Mackay score) |
Exclude non-CRSwNP pathologies; baseline polyp burden |
|
Endoscopy |
Nasal endoscopy (Lund-Kennedy score) |
Quantify polyp size, edema, secretions |
|
Symptom Scores |
SNOT-22, VAS (obstruction/olfaction), asthma control test (ACT) |
Baseline for efficacy monitoring |
|
Safety |
CBC, CMP, TB screen, hepatitis B/C serology |
Rule out contraindications; baseline organ function |
4.2 Monitoring Schedule
-
Short-term (Months 1–3): Monthly visits; assess symptom scores (SNOT-22/VAS), nasal endoscopy, and adverse events (AEs).
-
Long-term (Months 4–12):
-
Every 3 months: Biomarkers (eosinophils/IgE), ACT score, and AE review.
-
Every 6 months: Sinus CT (if symptoms worsen) and endoscopy to adjust therapy.
-
Response Definition:
-
Clinical Response: ≥20-point reduction in SNOT-22, ≥3-point reduction in nasal obstruction VAS, or improved olfaction.
-
Biomarker Response: Peripheral eosinophils ≤300 cells/μL, FeNO normalization in asthmatics.
-
Non-Response: Discontinue after 6 months if no clinical/biomarker improvement.
5. Efficacy & Safety Profiles
5.1 Key Efficacy Outcomes (Pooled Italian Real-World Data)
|
Biologic |
Polyp Size Reduction |
SNOT-22 Improvement |
Olfaction Recovery |
Asthma Control |
|
Dupilumab |
60%–70% |
25–30 points |
50%–60% |
40%–50% ACT improvement |
|
Mepolizumab |
50%–55% |
20–25 points |
40%–45% |
35%–40% ACT improvement |
|
Benralizumab |
50%–55% |
20–25 points |
40%–45% |
35%–40% ACT improvement |
|
Omalizumab |
45%–50% |
15–20 points |
30%–35% |
30%–35% ACT improvement |
5.2 Safety & AE Management
|
Adverse Event |
Incidence |
Management |
|
Injection-site reactions (erythema/pruritus) |
10%–15% |
Local cold compress; pre-medicate with antihistamines if recurrent |
|
Upper respiratory tract infections |
8%–12% |
Symptomatic treatment; discontinue if severe (≥7 days) |
|
Hypersensitivity reactions (anaphylaxis) |
<0.5% |
Immediate discontinuation; administer epinephrine |
|
Systemic effects (headache, fatigue) |
5%–8% |
Dose adjustment; switch to alternative biologic if persistent |
|
Eosinophilia paradox (rare) |
<1% |
Monitor for vasculitis; discontinue if organ involvement |
6. Perioperative & Special Scenario Management
6.1 Perioperative Biologic Use
-
Preoperative: Continue biologic therapy to reduce mucosal edema and intraoperative bleeding; avoid initiation within 4 weeks of surgery.
-
Postoperative: Resume biologic 2–4 weeks after ESS to prevent recurrence; combine with saline irrigation + INCS for 3 months.
6.2 COVID-19 Considerations (2021 Context)
-
Stable CRSwNP patients on biologics: Continue therapy; avoid in-person visits for monitoring (use telemedicine).
-
Active COVID-19 infection: Suspend biologic therapy until symptom resolution + 2 negative PCR tests.
-
Vaccination: Administer COVID-19 vaccine 2 weeks before/after biologic dosing; no evidence of reduced vaccine efficacy.
7. Core Multidisciplinary Recommendations
-
Conventional Therapy Priority: ESS + maximal medical therapy remains first-line; biologics are reserved for refractory type 2 CRSwNP.
-
Biologic Selection: Dupilumab is preferred for AERD/ severe polyposis; mepolizumab/benralizumab for eosinophil-predominant disease; omalizumab for atopic patients.
-
Monitoring Rigor: Mandate 6-monthly biomarker + endoscopic assessments to confirm response and adjust therapy.
-
Shared Decision-Making: Discuss risks/benefits (infection, cost, long-term commitment) with patients before initiating biologics.
-
Registry Participation: Enroll patients in Italian CRSwNP biologic registries to generate real-world evidence for future guidelines.